Sylvester Comprehensive Cancer Center

  • 20191076 - Hosein Peter

  • Investigator:
    Peter Hosein
    RCname Email

    Coordinator:

    IRB: 20191076

    SDG: Pancreatic, Liver, and Related Cancers
    Disease Site(s):

    Lip, Oral Cavity and Pharynx,Esophagus,Breast,Prostate,Bladder,Kidney,Other Urinary,Thyroid,Non-Hodgkin Lymphoma,Hodgkin Lymphoma,Stomach,Small Intestine,Colon,Rectum,Anus,Liver,Pancreas,Other Digestive Organ,Soft Tissue,Melanoma, skin

    Sponsor: EISAI

    Enrolling Sites:

    Sylvester

    Title:

    An Open-Label, Multicenter Phase 1/1b Study of Intratumorally Administered STING Agonist E7766 in Subjects With Advanced Solid Tumors or Lymphomas ? INSTAL-101

    Eligibility Criteria - NCT04144140 *This information has been extracted from " www.clinicaltrials.gov"

  • XL184-311 - Ikpeazu, Chukwuemeka

  • Investigator:
    Chukwuemeka Ikpeazu
    RCname Email

    Coordinator:

    IRB: 20190451

    SDG: Thyroid and Other Endocrine Cancers
    Disease Site(s):

    Thyroid

    Sponsor: Exelixis Pharmaceuticals

    Enrolling Sites:

    Deerfield
    Plantation
    Sylvester

    Title:

    A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study ofCabozantinib (XL184) in Subjects with Radioiodine-RefractoryDifferentiated Thyroid Cancer Who Have Progressed after PriorVEGFR-Targeted Therapy

    Eligibility Criteria - NCT03690388 *This information has been extracted from " www.clinicaltrials.gov"

  • TAB001-01 - Lockhart, Albert

  • Investigator:
    Albert Lockhart
    RCname Email

    Coordinator:

    IRB: 20190182

    SDG: Stomach and Esophageal Cancer
    Disease Site(s):

    Esophagus,Other Endocrine System,Colon

    Sponsor: TABS

    Enrolling Sites:

    Sylvester

    Title:

    TAB001-01: tle ICMJEA Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB001 in Subjects With Advanced Malignancies

    Eligibility Criteria - NCT03474640 *This information has been extracted from " www.clinicaltrials.gov"

  • BLU-667-1101 - Lopes, Gilberto

  • Investigator:
    Gilberto Lopes
    RCname Email

    Coordinator:
    RCemailImg Harshita Gahankari
    RCphone 3052430959

    IRB: 20170957

    SDG: Thoracic Oncology
    Disease Site(s):

    Thyroid,Other Endocrine System,Colon,Lung

    Sponsor: Blueprint Medicines

    Enrolling Sites:

    Sylvester

    Title:

    BLU-667-1101: A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors

    Eligibility Criteria - NCT03037385 *This information has been extracted from " www.clinicaltrials.gov"

  • C3851001 - Perez, Cesar

  • Investigator:
    Cesar Perez
    RCname Email

    Coordinator:
    RCemailImg Ximena Marincic-Sanchez
    RCphone 3052439200

    IRB: 20190114

    SDG: Stomach and Esophageal Cancer
    Disease Site(s):

    Lip, Oral Cavity and Pharynx,Esophagus,Cervix Uteri,Other Endocrine System,Lung

    Sponsor: PFIZER

    Enrolling Sites:

    Sylvester

    Title:

    C3851001: A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, and Pharmacodynamics Of Escalating Doses Of PF-06939999 (Prmt5 Inhibitor) In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer, Head And Neck Squamous Cell Carcinoma, Esophageal Cancer, Endometrial Cancer, CervicalCancer And Bladder Cancer

    Eligibility Criteria - NCT03854227 *This information has been extracted from " www.clinicaltrials.gov"

  • 20160985 - Schaefer Solle Natasha

  • Investigator:
    Natasha Schaefer Solle
    RCname Email

    Coordinator:

    IRB: 20160985

    SDG: Population Sciences
    Disease Site(s):

    Thyroid

    Sponsor: SCCC

    Enrolling Sites:

    Community Clinics
    Sylvester

    Title:

    Examining the association of Polybrominated Diphenyl Ethers (PBDE) and Thyroid function of South Florida Firefighters

  • MATCH - Slomovitz, Brian

  • Investigator:
    Brian Slomovitz
    RCname Email

    Coordinator:
    RCemailImg Carolina Troche
    RCphone 3052431481

    IRB: 20150671

    SDG: Gynecologic Cancer
    Disease Site(s):

    Cervix Uteri,Corpus Uteri,Ovary,Other Female Genital,Prostate,Kidney,Non-Hodgkin Lymphoma,Multiple Myeloma,Colon,Liver,Pancreas,Larynx,Soft Tissue,Kaposis sarcoma

    Sponsor: ECOG

    Enrolling Sites:

    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester

    Title:

    Molecular Analysis for Therapy Choice (MATCH)

    Eligibility Criteria - NCT02465060 *This information has been extracted from " www.clinicaltrials.gov"